Alpine Woods Capital Investors’s AC Immune ACIU Stock Holding History

Alpine Woods Capital Investors’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$200K	–	199
2022 Q1	$200K	Hold	50,000	–	–	0.02%	212
2021 Q4	$248K	Hold	50,000	–	–	0.02%	203
2021 Q3	$336K	Hold	50,000	–	–	0.04%	198
2021 Q2	$397K	Hold	50,000	–	–	0.04%	195
2021 Q1	$381K	Hold	50,000	–	–	0.04%	198
2020 Q4	$259K	Hold	50,000	–	–	0.03%	209
2020 Q3	$244K	Hold	50,000	–	–	0.04%	221
2020 Q2	$337K	Hold	50,000	–	–	0.06%	207
2020 Q1	$346K	Buy	50,000 +8,000	+19%	+$62.5K	0.08%	195
2019 Q4	$358K	Buy	+42,000	New	+$280K	0.07%	205

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Alpine Woods Capital Investors's ACIU Position: Q2 2022 in Review

Alpine Woods Capital Investors sold out of AC Immune (ACIU) in Q2 2022, closing a stake of 50,000 shares — an estimated $200K sold.

Alpine Woods Capital Investors first reported a position in ACIU in Q4 2019 and held it in 10 quarters. The position peaked at $397K in Q2 2021. 35 funds tracked by Wall St. Rank hold ACIU as of Q2 2022.

Alpine Woods Capital Investors reported no remaining AC Immune position as of Q2 2022 after selling out during the quarter.
Alpine Woods Capital Investors sold 50,000 AC Immune shares in Q2 2022, an estimated $200K.
Alpine Woods Capital Investors first reported a position in AC Immune in Q4 2019 and held it in 10 quarters.
Alpine Woods Capital Investors's AC Immune position peaked at $397K in Q2 2021.
35 funds tracked by Wall St. Rank held AC Immune as of Q2 2022.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2022, filed 2 Aug 2022.